MATADOR: A prospective, randomised, phase III biomarker trial in breast cancer patients
Description
A prospective, randomised, phase III biomarker trial (ISRCTN61893718) that run in 29 hospitals in the Netherlands. 664 Patients with an indication for adjuvant chemotherapy and a pT1-3, pN0-3 tumour were randomised 1:1 to 6 cycles of doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 2 weeks [dose dense (dd) AC] or docetaxel 75 mg/m2, doxorubicin 50 mg/m2, and cyclophosphamide 500 mg/m2 every 3 weeks (docetaxel-doxorubicin-cyclophosphamide; TAC) by means of the automated ALEA system (FormsVision BV) using Pocock minimization technique. Randomization was performed centrally at the Netherlands Cancer Institute. G-CSF (pegfilgrastim) was given to all patients. Radiotherapy and endocrine therapy were given according to the contemporary Dutch guidelines. Formalin-fixed paraffin-embedded (FFPE) material was collected between 2004 and 2012. RNA was isolated from FFPE tissue with a tumor cell percentage of at least 40% using the AllPrep DNA/RNA Mini Kit according to the manufacturer's instructions (Qiagen). Quantification and purity were measured using the NanoDrop 2,000 spectrophotometer and the 2,100 Bioanalyzer (Agilent Technologies). Libraries of cDNA were constructed with the TruSeq RNA Access Library Prep Kit (Illumina) and single-end sequenced using the HiSeq 2,500 (Illumina). Bulk mRNA sequencing data were analyzed using the RSEM package and the reads were aligned to the hg38 reference genome using STAR with default parameters.
Files
Institutions
Categories
Funding
Dutch Cancer Society
Amgen (United States)
Sanofi (United States)